English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021.

Dermatitis, Atopic / diagnosis Emollients / therapeutic use Glucocorticoids / therapeutic use Humans Ointments / therapeutic use Tacrolimus / therapeutic use
atopic dermatitis clinical practice guidelines clinical questions evidence-based medicine treatment

Journal

The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545

Informations de publication

Date de publication:
Oct 2022
Historique:
revised: 03 06 2022
received: 20 05 2022
accepted: 17 06 2022
pubmed: 23 8 2022
medline: 12 10 2022
entrez: 22 8 2022
Statut: ppublish

Résumé

This is the English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, descriptions of three new drugs, namely, dupilumab, delgocitinib, and baricitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Identifiants

DOI: 10.1111/1346-8138.16527 PMID: 35996152
pubmed: 35996152
doi: 10.1111/1346-8138.16527
doi:

Substances chimiques

Emollients 0
Glucocorticoids 0
Ointments 0
Tacrolimus WM0HAQ4WNM

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

e315-e375

Informations de copyright

© 2022 Japanese Dermatological Association.

Références

Kawashima M, Takigawa M, Nakagawa H, Furue M, Iijima M, Iizuka H, et al. Guidelines for management of atopic dermatitis. Jpn J Dermatol. 2000;110:1099-104.
Furue M, Furukawa F, Hide M, Takehara K, Japanese Dermatological Association. Guidelines for therapy for atopic dermatitis 2003. Jpn J Dermatol. 2003;113:451-7.
Furue M, Furukawa F, Hide M, Takehara K. Japanese Dermatological Association Guidelines for therapy of atopic dermatitis 2004. Jpn J Dermatol. 2004;114:135-42.
Furue M, Saeki H, Furukawa F, Hide M, Ohtsuki M, Nakamura T, et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol. 2008;118:325-42.
Furue M, Saeki H, Furukawa F, Ohtsuki M, Katayama I, Sasaki R, et al. Guidelines for therapy of atopic dermatitis. Jpn J Dermatol. 2009;119:1515-34.
Katoh N, Saeki H, Nakahara T, Tanaka A, Kabashima K, Sugaya M, et al. Guidelines for therapy of atopic dermatitis 2016. Jpn J Dermatol. 2016;126:121-55.
Kohno Y, Yamamoto S, The Study Group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 1999. (In Japanese).
Furue M, Yamamoto S, The Study Group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 2001. (In Japanese).
Kohno Y, Yamamoto S, The Study Group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 2005. (In Japanese).
Kohno Y, Yamamoto S, The Study Group for Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of atopic dermatitis 2006. (In Japanese).
Katayama I, Kohno Y, Japanese Society of Allergology. Japanese guideline for atopic dermatitis 2009. Kyowa Kikaku: Tokyo; 2009 (In Japanese).
Katayama I, Kohno Y, Japanese Society of Allergology. Japanese guideline for atopic dermatitis 2012. Kyowa Kikaku: Tokyo; 2012 (In Japanese).
Katayama I, Kohno Y, Japanese Society of Allergology. Japanese guideline for atopic dermatitis 2015. Kyowa Kikaku: Tokyo; 2015 (In Japanese).
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. Jpn J Dermatol. 2018;128:2431-502.
Committee for Nasal Allergy Guidelines. Nasal allergy guidelines 2020. Tokyo: Life Science; 2020 (In Japanese).
Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol. 2005;125:183-200.
Melnik B, Hollmann J, Plewig G. Decreased stratum corneum ceramides in atopic individuals-a pathobiochemical factor in xerosis? Br J Dermatol. 1988;119:547-9.
Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016;42:1-8.
Kono M, Nomura T, Ohguchi Y, Mizuno O, Suzuki S, Tsujiuchi H, et al. Comprehensive screening for a complete set of Japanese-population-specific filaggrin gene mutations. Allergy. 2014;69:537-40.
De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127:773-86.
Tokumasu R, Yamaga K, Yamazaki Y, Murota H, Suzuki K, Tamura A, et al. Dose-dependent role of claudin-1 in vivo in orchestrating features of atopic dermatitis. Proc Natl Acad Sci USA. 2016;113:E4061-8.
Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci USA. 2009;106:21795-800.
Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43:29-40.
Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66:8-13.
Kamide R. Assessment of pruritus. Jpn J Dermatol. 2005;115:1764-70. (In Japanese).
Papoiu AD, Wang H, Coghill RC, Chan YH, Yosipovitch G. Contagious itch in humans: a study of visual ‘transmission’ of itch in atopic dermatitis and healthy subjects. Br J Dermatol. 2011;164:1299-303.
Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology. 2004;27:212-7.
Murota H, Katayama I. Evolving understanding on the aetiology of thermally provoked itch. Eur J Pain. 2016;20:47-50.
Murota H. Somatic sensation and pruritus. Rinsho Derma. 2020;62:435-43. (In Japanese).
Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Sota H, Kemany L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411-7.
Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171:217-28.
Shiratori-Hayashi M, Koga K, Tozaki-Saitoh H, Kohro Y, Toyonaga H, Yamaguchi C, et al. STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch. Nat Med. 2015;21:927-31.
Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol. 2014;41:205-12.
Azimi E, Reddy VB, Pereira PJS, Talbot S, Woolf CJ, Lerner EA. Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol. 2017;140:447-453.e3.
Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet. 2012;44:1222-6.
Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl. 1991;165:1-53.
Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103:125-38.
Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947-54.
Morita E. Analysis of prevalence and identification of causative and exacerbation factors of atopic dermatitis. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. 2002;2:184-186. (In Japanese).
Yamamoto S. Analysis of prevalence and identification of causative and exacerbation factors of atopic dermatitis and studies for improvement of living environment to prevent the development and exacerbation of symptoms. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. 2003;1:71-77. (In Japanese).
Saeki H, Iizuka H, Mori Y, Akasaka T, Takagi H, Kitajima Y, et al. Prevalence of atopic dermatitis in Japanese elementary schoolchildren. Br J Dermatol. 2005;152:110-4.
Saeki H, Oiso N, Honma M, Iizuka H, Kawada A, Tamaki K. Prevalence of atopic dermatitis in Japanese adults and community validation of the U.K. diagnostic criteria. J Dermatol Sci. 2009;55:140-1.
Ueda H. Epidemiology of atopic dermatitis. Jpn J Ped Med. 2000;32:986-92. (In Japanese).
Mikawa H. Epidemiological research of atopic dermatitis. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. 1995;247-251. (In Japanese).
Ohta K, Oka N, Okazaki K, Okazaki R, Okabe T, Okuma M, et al. Prevalence of atopic dermatitis in elementary schools in western Japan: Comparison between 1992 and 2002. Jpn J Pediatr Allergy Clin Immunol. 2003;17:255-68. (In Japanese).
Kusunoki T, Morimoto T, Nishikomori R, et al. Changing prevalence and severity of childhood allergic diseases in Kyoto, Japan, from 1996 to 2006. Allergol Int. 2009;58:543-8.
Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M. Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors association with concomitant allergic diseases. J Am Acad Dermatol. 2006;55:765-71.
Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113:925-31.
Sandstrom MH, Faergemann J. Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study. Br J Dermatol. 2004;150:103-10.
Kohno Y. Identification of causative and exacerbation factors of atopic dermatitis and studies for improvement of living environment to prevent the development and exacerbation of symptoms. Reports of Research on Allergic Disease and Immunology by Ministry of Health, Labour and Welfare of Japan. 2009;1-11. (In Japanese).
Fukiwake N, Furusyo N, Kubo N, et al. Incidence of atopic dermatitis in nursery school children -a follow-up study from 2001 to 2004, Kyushu University Ishigaki Atopic Dermatitis Study (KIDS). Eur J Dermatol. 2006;16:416-9.
Ohshima Y, Yamada A, Hiraoka M, et al. Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of a 4-year followup study. Ann Allergy Asthma Immunol. 2002;89:265-70.
Shibuya N, Saito E. Natural course of sensitization and allergic diseases from birth to age 4 years. Jpn J Pediatr Allergy Clin Immunol. 2015;29:284-93.
Yamamoto-Hanada K, Yang L, Saito-Abe M, et al. Four phenotypes of atopic dermatitis in Japanese children: A general population birth cohort study. Allergol Int. 2019;68:521-3.
Yamamoto-Hanada K, Pak K, Saito-Abe M, et al. Allergy and immunology in young children of Japan: The JECS cohort. World Allergy Organ J. 2020;13:100479.
Anan S, Yamamoto N. Natural remission of atopic dermatitis. Skin Res. 1996;38(Suppl 18):13-6. (In Japanese).
Wakamori T, Katoh N, Hirano S, Kishimopto S, Ozasa K. Atopic dermatitis, dry skin and serum IgE in children in a community in Japan. Int Arch Allergy Immunol. 2009;149:103-10.
Katoh N, Hirano S, Kishimoto S. Prognostic factor of adult patients with atopic dermatitis. J Dermatol. 2008;35:477-83.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm-Venereol. 1980;92(Suppl):44-7.
Williams HC, Burney PGJ, Pembroke AC, Hay RJ. The UK Working Party's Diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131:406-16.
Aoki T, Fukuzumi J, Adachi J, Endo K, Kojima M. Re-evaluation of skin lesion distribution in atopic dermatitis. Acta Derm Venereol. 1992;176(Suppl):19-23.
Hsu AP, Davis J, Puck JM, Holland SM, Freeman AF. Autosomal Dominant Hyper IgE Syndrome. Accessed March 2, 2021. http://www.ncbi.nlm.nih.gov/books/NBK25507/
Aoki T. The second report from the Advisory Committee for Atopic Dermatitis Severity Classification. Jpn J Dermatol. 2001;111:2023-33. (In Japanese).
Yoshida H. Interim report from the Advisory Committee for Atopic Dermatitis Severity Classification. Jpn J Dermatol. 1998;108:1491-6. (In Japanese).
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology. 1993;186:23-31.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-8.
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-32.
Kawashima M, Harada S, Tango T. Evaluation of the itch based on a new rating scale using patient diary. Jpn J Clin Dermatol. 2002;56:692-7.
Ebata T, Ishiuji Y, Saeki H, Nakagawa H. Development of the Japanese Version of the 5-D itch Scale. Jpn J Dermatol. 2015;125:1035-40.
Murray CS, Rees JL. Are subjective accounts of itch to be relied on? The lack of relation between visual analogue itch scores and actigraphic measures of scratch. Acta Derm Venereol. 2011;91:18-23.
Ikoma A, Ebata T, Chantalat L, et al. Measurement of nocturnal scratching in patients with pruritus using a smartwatch: Initial clinical studies with the itch tracker app. Acta Derm Venereol. 2019;99:268-73.
Noro Y, Omoto Y, Umeda K, et al. Novel acoustic evaluation system for scratching behavior in itching dermatitis: rapid and accurate analysis for nocturnal scratching of atopic dermatitis patients. J Dermatol. 2014;41:233-8.
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140:1513-9.
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326-32.
Gaunt DM, Metcalfe C, Ridd M. The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference. Allergy. 2016;71:1620-5.
Stalder JF, Barbarot S, Wollenberg A, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66:1114-21.
Howells L, Chalmers JR, Gran S, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol. 2020;183:524-36.
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Med Res Opin. 2020;36:367-76.
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2021;185:139-46. https://doi.org/10.1111/bjd.19751
Takahashi N, Suzukamo Y, Nakamura M, et al. Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes. 2006;4:46.
Fukuhara S, Suzukamo Y. Japanese version of DLQI and Skindex-29. Allergy Pract. 2007;358:23-7. (In Japanese).
Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM. The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol. 2002;29:693-8.
Ohya Y, Sasaki R, Matsumoto M, et al. Development of Japanese Version of Children's Dermatology Life Quality Index (CDLQI). Jpn J Allergol. 2002;51:265 (In Japanese).
Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942-9.
Kondo-Endo K, Ohashi Y, Nakagawa H, Katsunuma T, Ohya Y, Kamibeppu K, et al. Development and validation of a questionnaire measuring quality of life in primary caregivers of children with atopic dermatitis (QPCAD). Br J Dermatol. 2009;161:617-25.
Katsunuma T, Tan A, Ohya Y. Short version of quality of life questionnaire in primary caregivers of children with atopic dermatitis (QPCAD): development and validation of QP9. Jpn J Allergol. 2013;62:33-46. (In Japanese with English abstract).
Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai J-S, et al. Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol. 2005;125:1106-11.
Yamaguchi C, Futamura M, Chamlin SL, Ohya Y, Asano M. Development of a Japanese Culturally Modified Version of the Childhood Atopic Dermatitis Impact Scale (JCMV-CADIS). Allergol Int. 2016;65:312-9.
Smith PH, Ownby DR. Clinical significance of immunoglobulin E. In: Adkinson NF Jr, Bochner BS, Burks AW, et al., editors. Middleton's allergy, principles and practice. Philadelphia, PA: Mosby; 2014. p. 1108-19.
Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci. 2006;43:75-84.
Tamaki K, Saeki H, Kadono T, Sato S, Hatta N, Hasegawa M, et al. Serum TARC/CCL17 levels as a disease marker of atopic dermatitis. Jpn J Dermatol. 2006;116:27-39. (In Japanese with English abstract).
Fujisawa T, Nagao M, Noma Y, Suzaki Y, Furukawa R, Iguchi M, et al. Clinical Utility serum TARC/CCL17 for monitoring clinical course of atopic dermatitis in children. Jpn J Pediatr Allergy Clin Immunol. 2005;19:744-57. (In Japanese with English abstract).
Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 2014;41:221-9.
Fujisawa T, Nagao M, Hiraguchi Y, Tatsumata H, Nishimori H, Iguchi K, et al. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. Pediatr Allergy Immunol. 2009;20:633-41.
Bartuski AJ, Kamachi Y, Schick C, Overhauser J, Silvermanet GA. Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics. 1997;43:321-8.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40:1621-8.
Nagao M, Inagaki S, Kawano T, Azuma Y, Nomura N, Noguchi Y, et al. SCCA2 is a reliable biomarker for evaluating pediatric atopic dermatitis. J Allergy Clin Immunol. 2018;141:1934-1936.e11.
Okawa T, Yamaguchi Y, Kou K, Ono J, Azuma Y, Komitsu N, et al. Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients. Allergol Int. 2018;67:124-30.
Sivaprasad U, Kinker KG, Ericksen MB, Lindsey M, Gibson AM, Bass SA, et al. SERPINB3/B4 contributes to early inflammation and barrier dysfunction in an experimental murine model of atopic dermatitis. J Invest Dermatol. 2015;135:160-9.
Takeuchi S, Furusyo N, Ono J, Azuma Y, Takemura M, Esaki H, et al. Serum squamous cell carcinoma antigen (SCCA)-2 correlates with clinical severity of pediatric atopic dermatitis in Ishigaki cohort. J Dermatol Sci. 2019;95:70-5.
Yuyama N, Davies DE, Akaiwa M, Masui K, Hamasaki Y, Suminami Y, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19:287-96.
Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol. 1996;13:239-45.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1-191.
National Institute for Health and Care Excellence Guidance. Frequency of application of topical corticosteroids for atopic eczema. 2004. Accessed March 2, 2021. Available from: http://www.nice.org.uk/guidance/ta81/resources/guidance
Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exp Dermatol. 1991;16:444-7.
Long CC, Finlay AY, Averill RW. The rule of hand: 4hand area = 2 FTU = 1 g. Arch Dermatol. 1992;128:1129-30.
Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol. 2005;152:130-41.
Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess. 2004;8:1-120.
Feldman RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48:181-3.
Hajar T, Lesham YA, Hanifin JM, Nedorost S, Lio PA, Paller AS, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72:541-9.
Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5:416-25.
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15.
Haeck IM, Hamdy NA, Timmer-de Mik L, Lenties EGWM, Verhaar HJJ, Knol MJ, et al. Low bone mineral density in adult patients with moderate to severe atopic dermatitis. Br J Dermatol. 2009;161:1248-54.
Vestergaard P. Skeletal effects of systemic and topical corticosteroids. Curr Drug Saf. 2008;3:190-3.
van Velsen SG, Knol MJ, van Eijk RL, de Vroeda MA, de Wit TC, Lam MGEH, et al. Bone mineral density in children with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2010;63:824-31.
Furue M. Topical corticosteroids: how to use in clinical practice. Jpn J Allergol. 2009;58:491-7.
Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs. 1988;36(Suppl 5):15-23.
Takeda K, Harada T, Asato T, Ishimoto A, Nomoto M, Kuramoto M. Review on systemic effects of topical corticosteroids - with special reference to adrenocortical suppression following percutaneous absorption. J Clin Exp Med. 1977;101:817-29. (In Japanese).
Shimao S. Problems regarding side effects of corticosteroid therapy in the field of dermatology. Nishinihon J Dermatol. 1978;40:5-24. (In Japanese with English abstract).
Wood Heickman LK, Davallow Ghajar L, Conaway M, Rogol AD. Evaluation of hypothalamic-pituitary-adrenal axis suppression following cutaneous use of topical corticosteroids in children: A meta-analysis. Horm Res Paediatr. 2018;89:389-96.
Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol. 2014;59:456-9.
Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol. 2003;148:128-33.
Furue M, Terao H, Moroi Y, Koga T, Kubota Y, Nakayama J, et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol. 2004;31:277-83.
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part II: Ocular disease secondary to treatments. Am J Clin Dermatol. 2019;20:807-15.
Hsu JI, Pflugfelder SC, Kim SJ. Ocular complications of atopic dermatitis. Cutis. 2019;104:189-93.
Nakano E, Iwasaki T, Osanai T, Yamamoto K, Miyauchi M. Ocular complications of atopic dermatitis. Jpn J Ophthalmol Soc. 1997;101:64-8. (In Japanese).
Nakagawa N, Tsukahara Y, Tetsumoto K. Statistical analysis of clinical risk factors associated with atopic cataract occurrence. J Eye. 2000;17:1679-84. (In Japanese).
Yamamoto K, Wakabayashi Y, Kawakami S, et al. Recent trends of ocular complications in patients with atopic dermatitis. Jpn J Ophthalmol. 2019;63:410-6.
Goto H, Sanada A, Wakabayashi Y, Yagihashi T, Iwasaki T, Usui M, et al. The role of trauma in the pathogenesis of atopic cataract. J Eye. 1996;13:1728-32. (In Japanese).
Hirano S, Katoh N, Yasuno H. A retrospective analysis of the severity of atopic dermatitis. Jpn J Dermatol. 1995;105:1309-15. (In Japanese with English abstract).
Furue M, Kawashima M, Furukawa F, Iizuka H, Ito M, Nakagawa H, et al. Clinical epidemiology: a prospective questionnaire study for atopic dermatitis patients (part 2). Jpn J Clin Dermatol. 2001;65:83-92. (In Japanese).
Taniguchi H, Ohki O, Yokozeki H, Katayama I, Tanaka A, Kiyosawa M, et al. Cataract and retinal detachment in patients with severe atopic dermatitis who were withdrawn from the use of topical corticosteroid. J Dermatol. 1999;26:658-65.
Uchiyama M, Sugiura H, Uehara M, Nakamura J, Kani K. Atopic cataract: recent occurrence and inducing factor of cataract. Rinsho Derma. 1996;38:61-4. (In Japanese).
Arikawa J, Higaki Y, Takamura E, Kawashima M. A study of intraocular pressure in patients with atopic dermatitis and topical steroid treatment on the face. Jpn J Dermatol. 2002;112:1107-10. (In Japanese with English abstract).
Japanese FK, 506 Ointment Study Group. Clinical guidance for treatment of patients with atopic dermatitis by tacrolimus ointment 0.1% and 0.03%. Jpn J Clin Dermatol. 2003;57:1217-34. (In Japanese with English abstract).
Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808-16.
Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium-to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219:7-21.
Maruho Co., Ltd. Results of a post-marketing survey regarding Protopic® ointment 0.03% for children, May, 2019 (In Japanese).
Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178:424-32.
Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82:823-31.
Nakagawa H, Nemoto O, Igarashi A, Saeki H, Murata R, Kaino H, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47:114-20.
Nakamura K, Futamura M, Tsunemi Y, Tanese K, Katoh N. Manual for the safe use of delgocitinib ointment (CORECTIM® Ointment 0.5%). Jpn J Dermatol. 2020;130:1581-8. (In Japanese).
Ring J, Alomar A, Bieber T, Deleuran H, Fink-Wagner A, Gemetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26:1176-93.
Caproni M, Torchia D, Antiga E, et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. Br J Dermatol. 2007;156:312-9.
Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. 2004;114:887-95.
Schmitt J, von Kobyletzki L, Svensson Å, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164:415-28.
Saito R, Tanaka A, Hiragun T, Iwamoto K, Takahagi S, Takahashi M, et al. Reduction of serum thymus and activation-regulated chemokine after short-term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis. J Dermatol. 2019;46:e486-7.
Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;2019:CD012167.
Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E. Oral H1 antihistamines as monotherapy for eczema. Cochrane Database Syst Rev. 2013;2013:CD007770.
Yanai K. Ideal treatment with antihistamines from the viewpoint of pharmacological actions. J Otolaryngol Jpn. 2020;123:196-204. (In Japanese).
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606-19.
Study Group of Neoral® Treatment for Atopic Dermatitis. Treatment: safety and efficacy of intermittent cyclosporin MEPC therapy in patients with severe adult atopic dermatitis: multicenter, openlabel, long-term clinical trial. Jpn J Clin Dermatol. 2009;63:163-71. (In Japanese).
Kim JE, Shin JM, Ko JY, Ro YS. Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine. Dermatol Ther. 2016;29:120-5.
Hashizume H, Ito T, Yagi H, et al. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol. 2007;34:430-4.
Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol. 2011;155:141-8.
Kobayashi H, Ishii M, Takeuchi S, et al. Efficacy and safety of a traditional herbal medicine, Hochu-ekki-to in the long-term management of Kikyo (delicate constitution) patients with atopic dermatitis: a 6-month, multicenter, double-blind, randomized, placebo-controlled study. Evid Based Complement Alternat Med. 2010;7:367-73.
Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol. 1992;126:179-84.
Sheehan MP, Rustin MHA, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet. 1992;340:13-7.
Fung AY, Look PC, Chong LY, But PP, Wong E. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol. 1999;38:387-92.
O'Shea JJ, Plenge R. JAKs and STATs in immunoregulation and immune-mediated disease. Immunity. 2012;36:542-50.
Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242-55.
Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80:913-21.
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333-43.
Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35:476-85.
Ministry of Health, Labour and Welfare. Guidelines for promoting optimal use, Baricitinib (Trade name: Oluminant tablets 2 mg, Oluminant tablets 4 mg) ‘Atopic dermatitis’. Accessed March 2, 2021. Available from: https://www.pmda.go.jp/files/000238112.pdf (In Japanese).
Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Matters to be considered for the preparation of guidelines for promoting optimal use regarding Janus kinase inhibitors. HIB/MED 1225-3, December 25, 2020. (In Japanese).
Chang HY, Nadeau KC. IL-4Rα inhibitor for atopic disease. Cell. 2017;170:222.
Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35-50.
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345-60.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.
Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242:233-46.
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40-52.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-48.
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour J-P, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156:131-43.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287-303.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82:377-88.
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cark MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083-101.
Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21:567-77.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:850-78.
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120:10-22.e2.
Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F, Pigatto PD. Italian guidelines for therapy of atopic dermatitis-adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019;32:e13121.
Ministry of Health, Labour and Welfare. Guidelines for promoting optimal use, Dupilumab (Genetical Recombination) (Trade name: DUPIXENT S.C. Injection 300 mg syringe, DUPIXENT S.C. Injection 300 mg pen) ‘Atopic dermatitis’. April 2018 (revised in November 2020). Accessed March 2, 2021. Available from: https://www.pmda.go.jp/files/000237673.pdf (In Japanese).
Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Matters to be considered for the preparation of guidelines for promoting optimal use regarding anti-IL-4 receptor α subunit antibody preparations. HIB/MED 0417-5, April 17, 2018 (In Japanese).
Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Modification of matters to be considered for the preparation of guidelines for promoting optimal use regarding anti-IL-4 receptor α subunit antibody preparations. HIB/MED 0326-3, March 26, 2019 (In Japanese).
Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Modification of matters to be noticed that were established by the Minister of Health, Labour and Welfare based on the Rules for Health Insurance-covered Medical Facilities and Medical Practitioners, Rules for Health Insurance-covered Pharmacies and Pharmacists, and Standards for Health Insurance-covered Medical Facilities and Medical Practitioners. HIB/MED 0426-3, April 26, 2019 (In Japanese).
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459-73.
Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33:1224-31.
Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand. 2002;81:234-9.
Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology. 1997;56:335-40.
Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;2015:CD007346.
Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy. JAMA Dermatol. 2016;152:934-5.
Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population-based cohort study. J Invest Dermatol. 2011;131:884-91.
Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol. 2013;149:1274-80.
Chi CC, Kirtschig G, Aberer W, Gabbud J-P, Lipozencic J, Karpati S, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad Dermatol Venereol. 2017;31:761-73.
Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64:559-65.
Loden M, Andersson AC, Andersson C, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol. 2002;82:45-7.
Kawashima M, Numano K, Ishizaki C. Usefulness of moisturizers for dermato-physiological dysfunction in patients with atopic dermatitis. Jpn J Dermatol. 2007;117:969-77. (In Japanese with English abstract).
van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Sys Rev. 2017;2017:CD012119.
Ohtani M, Ohtani M, Nozawa A, Matsumoto M, Yamamura K, Koshigeda M, et al. A study of the influence of the volume and frequency of application on the efficacy of moisturizers. Jpn J Dermatol. 2012;122:39-43. (In Japanese).
Nakamura M, Uemura K, Nemoto O, Miyachi Y. Evaluation of an optimal method for topical application of moisturizer. Skin Res. 2006;5:311-6. (In Japanese with English Abstract).
Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol. 1985;65:102-5.
Kawashima M, Hayashi N, Nogita T, Yanagisawa K, Mizuno A. The usefulness of moisturizers for maintenance of remission in atopic dermatitis. Jpn J Dermatol. 2007;117:1139-45. (In Japanese with English abstract).
Denda M, Sokabe T, Fukumi-Tominaga T, Tominaga M. Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol. 2007;127:654-9.
Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology. 2004;62:212-7.
Murota H, Izumi M, Abd El-Latif MI, et al. Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. J Allergy Clin Immunol. 2012;130:671-82.
Cheng X, Jin J, Hu L, et al. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell. 2010;141:331-43.
Uehara M, Takada K. Use of soap in the management of atopic dermatitis. Clin Exp Dermatol. 1985;10:419-25.
Uehara M. Use of soap in bathing for atopic dermatitis. Rinsho Derma. 1981;23:1049-52. (In Japanese).
Fonacier LS, Aquino MR. The role of contact allergy in atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:337-50.
Giordano-Labadie F, Rance F, Pellegrin F, Bazex J, Dutau G, Schwarze HP. Frequency of contact allergy in children with atopic dermatitis: results of a prospective study of 137 cases. Contact Dermatitis. 1999;40:192-5.
Tamagawa-Mineoka R, Masuda K, Ueda S, Nakamura N, Hotta E, Hattori J, et al. Contact sensitivity in patients with recalcitrant atopic dermatitis. J Dermatol. 2015;42:720-2.
Takayama K, Yokozeki H, Matsunaga K, Katayama I, Aiba S, Ikezawa Z, et al. Guidelines for contact dermatitis 2020. Jpn J Dermatol. 2020;130:523-67.
Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database Syst Rev. 2008;2008:CD005203.
Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Cochrane Database Syst Rev. 2012;2012:CD000133.
Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999;104:1280-4.
Sulzberger MB, Herrmann F, Zak FG. Studies of sweating; preliminary report with particular emphasis of a sweat retention syndrome. J Invest Dermatol. 1947;9:221-42.
Shiohara T, Doi T, Hayakawa J. Defective sweating responses in atopic dermatitis. Curr probl Dermatol. 2011;41:68-79.
Eishi K, Lee JB, Bae SJ, Takenaka M, Katayama I. Impaired sweating function in adult atopic dermatitis: results of the quantitative sudomotor axon reflex test. Br J Dermatol. 2001;147:683-8.
Kijima A, Murota H, Matsui S, Takahashi A, Kimura A, Kitaba S, et al. Abnormal axon reflex-mediated sweating correlates with high state of anxiety in atopic dermatitis. Allergol Int. 2012;61:469-73.
Takahashi A, Murota H, Matsui S, Kijima A, Kiaba S, Lee J-B, et al. Decreased sudomotor function is involved in the formation of atopic eczema in the cubital fossa. Allergol Int. 2013;62:473-8.
Yamaga K, Murota H, Tamura A, Miyata H, Ohmi M, Kikuta J, et al. Claudin-3 loss causes leakage of sweat from the sweat gland to contribute to the pathogenesis of atopic dermatitis. J Invest Dermatol. 2018;138:1279-87.
Hiragun T, Ishii K, Hiragun M, Suzuki H, Kan T, Mihara S, et al. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol. 2013;132:608-15.
Imayama S, Shimozono Y, Hoashi M, Yasumoto S, Ohta S, Yoneyama K, et al. Reduced secretion of IgA to skin surface of patients with atopic dermatitis. J Allergy Clin Immunol. 1994;94:195-200.
Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol. 2005;174:8003-10.
Ono E, Murota H, Mori Y, Yoshioka Y, Nomura Y, Munetsugu T, et al. Sweat glucose and GLUT2 expression in atopic dermatitis: Implication for clinical manifestation and treatment. PLoS One. 2018;13:e0195960.
Murota H, Katayama I. Lifestyle guidance for pediatric patients with atopic dermatitis based on age specific physiological function of skin. Pediatr Allergy Immunol Pulmonol. 2016;29:196-201.
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850-9.
Harkins CP, Pettigrew KA, Oravcová K, Gardner J, Hearn RMR, Rice D, et al. The microevolution and epidemiology of Staphylococcus aureus colonization during atopic eczema disease flare. J Invest Dermatol. 2018;138:336-43.
Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity. 2015;42:756-66.
Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163:12-26.
Savolainen J, Lammintausta K, Kalimo K, Viander M. Candida albicans and atopic dermatitis. Clin Exp Allergy. 1993;23:332-9.
Takechi M. Minimum effective dosage in the treatment of chronic atopic dermatitis with itraconazole. J Int Med Res. 2005;33:273-83.
Mayser P, Kupfer J, Nemetz D, Schafer U, Nilles M, Hort W, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream - results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2006;19:153-8.
Ohya Y. From classics in psychosomatic medicine to current behavioral medicine for allergic disease. Jpn J Psychosom Med. 2018;58:376-83. (In Japanese).
Horev A, Freud T, Manor I, Cohen AD, Zvulunov A. Risk of attention-deficit/hyperactivity disorder in children with atopic dermatitis. Acta Dermatovenerol Croat. 2017;25:210-4.
Mochizuki H, Tanaka S, Morita T, Wasaka T, Sadato N, Kakigi R. The cerebral representation of scratching-induced pleasantness. J Neurophysiol. 2014;111:488-98.
Arakawa H, Shimojo N, Katoh N, Hiraba K, Kawada Y, Yamanaka K, et al. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergol Int. 2020;69:84-90.
Lack G, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. N Engl J Med. 2003;348:977-85.
Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol. 2008;122:984-91.
Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137:1071-8.
Miyaji Y, Yang L, Yamamoto-Hanada K, Narita M, Saito H, Ohya Y. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age. J Allergy Clin Immunol Pract. 2020;8:1721-1724.e6.
Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818-23.
Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134:824-30.
Natsume O, Kabashima S, Nakazato J, Yamamoto-Hanada K, Narita M, Kondo M, et al. Two-step egg introduction for preventing egg allergy in high-risk infants with eczema (PETIT study): a randomized, double-blind, placebo-controlled trial. Lancet. 2017;389:276-86.
Fukuie T, Ohya Y, Ebisawa M, Ito H, Aihara Y, Ito S, et al. Proposal for prevention of hen's egg allergy. Jpn J Pediatr Allergy Clin Immunol. 2017;31:i-x. (In Japanese).
Japanese Society for Pediatric Allergy and Clinical Immunogy. Japanese pediatric guideline for food allergy 2016. Tokyo: Kyowa Kikaku; 2016 (In Japanese).
Iikura Y, Odasima Y, Kitabayashi T, Nakagawa K, Sakai N, Yamada S, et al. Relationship between cedar pollen and some allergic symptoms. Allergol Immunol. 2002;9:343-9. (In Japanese).
Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136:96-103.
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases. Am J Clin Dermatol. 2019;20:797-805.
Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77:280-6.
Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996;23:1091-8.
Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012;64:148-55.
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327-49.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657-82.
Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo (chemo) therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170:501-13.
Morita A, Etoh T, Torii H, Ito T, Nemoto O, Kamide R, et al. Guidelines for phototerapy in psoriasis. Jpn J Dermatol. 2016;126:1239-62. (In Japanese).
Mukai H, Fukuda H, Suzuki T, Saotome A, Hayade E. Usefulness of inpatient care for atopic dermatitis: a questionnaire survey in patients with a history of hospitalization. Skin Res. 2012;11(Suppl 18):43-7. (In Japanese with English Abstract).
Kataoka Y. Consideration of quality index in clinical practice of atopic dermatitis. J Visual Dermatol. 2014;13:1094-7. (In Japanese).
Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332:933-8.
Moore EJ, Williams A, Manias E, Varigos G, Donath S. Eczema workshops reduce severity of childhood atopic eczema. Australas J Dermatol. 2009;50:100-6.
Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K. Effects of a short-term parental education program on childhood atopic dermatitis: a randomized controlled trial. Pediatr Dermatol. 2013;30:438-43.
Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64:502-7.
Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2014;2014:CD004054.
Department of Dermatology, Kyushu University. Let's think about atopic dermatitis together. Accessed March 2, 2021. Available from: https://www.kyudai-derm.org/atopy/index.html.2013 (In Japanese)
Environmental Restoration and Conservation Agency. Handbook of pediatric atopic dermatitis Prevention for exacerbation of asthma. 2009. Accessed March 2, 2021. Available from: https://www.erca.go.jp/yobou/pamphlet/form/00/archives_1028.html. (In Japanese)
Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy. 1999;29:342-6.
Panduru M, Panduru NM, Sălăvăstru CM, Tiplica G-S. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29:232-42.
Jiang W, Ni B, Liu Z, Liu X, Xie W, Wu IXY, et al. The role of probiotics in the prevention and treatment of atopic dermatitis in children: An updated systematic review and meta-analysis of randomized controlled trials. Paediatr Drugs. 2020;22:535-49.
Cuello-Garcia C, Fiocchi A, Pawankar R, Yepes-Nunez JJ, Morgano GP, Zhang Y, et al. Prebiotics for the prevention of allergies: A systematic review and meta-analysis of randomized controlled trials. Clin Exp Allergy. 2017;47:1468-77.
Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L, García-Romero MT. Synbiotics for prevention and treatment of atopic dermatitis: A meta-analysis of randomized clinical trials. JAMA Pediatr. 2016;170:236-42.
Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, Murrell DF, Tang MLK, Roberts A, et al. Probiotics for treating eczema. Cochrane Database Syst Rev. 2018;2018:CD006135.
Koga Y, Tokunaga S, Nagano J, Sato F, Konishi K, Tochio T, et al. Age-associated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermatitis infants. Pediatr Res. 2016;80:844-51.
Shibata R, Kimura M, Takahashi H, Mikami K, Aiba Y, Takeda H, et al. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. Clin Exp Allergy. 2009;39:1397-403.
Boženský J, Hill M, Zelenka R, Skýba T. Prebiotics do not influence the severity of atopic dermatitis in infants: a randomised controlled trial. PLoS One. 2015;10:e0142897.
Hide M, Yamamura Y, Morita E, Kohro O, Yamamoto S. Alternative treatments for atopic dermatitis: classification of the treatments and a questionnaire study. Nishinihon J Dermatol. 2000;62:83-8. (In Japanese with English Abstract).
Sato M, Yamamoto-Hanada K, Yang L, Irahara M, Ishikawa F, Iwama-Mitsui M, et al. Complementary and alternative medicine and atopic dermatitis in children. J Dermatol Sci. 2020;97:80-2.
Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr dermatol. 2013;30:29-35.
Takehara K, Iizuka H, Itoh M, Tamaki K, Kawashima M, Shiohara T, et al. Survey of health damage caused by inadequate treatment for atopic dermatitis. Jpn J Dermatol. 2000;110:1095-8. (In Japanese).
Pfab F, Huss-Marp J, Gatti A, Fuqin J, Athanasiadis GI, Irnich D, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. Allergy. 2010;65:903-10.
Siebenwirth J, Luedtke R, Remy W, Rakoski J, Borelli S, Ring J. Effectiveness of a classical homeopathic treatment in atopic eczema. A randomised placebo-controlled double-blind clinical trial. Forsch Komplementmed. 2009;16:315-23.
World Health Organization. Adherence to long-term therapies - Evidence for action. 2003. Accessed March 2, 2021. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf
Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease-strategies for optimizing treatment outcome. J EurAcad Dermatol Venereol. 2019;33:2253-63.
Ascertaining barriers for compliance: policies for safe, effective and costeffective use of medicines in Europe. Final report of the ABC project 2012. Accessed March 2, 2021. Available from: http://www.ABCproject.eu
Ou HT, Feldman SR, Balkrishnan R. Understanding and improving treatment adherence in pediatric patients. Semin Cutan Med Surg. 2010;29:137-40.
Masuko I. Introduction, Japanese Society of Pediatric Intractble Asthma and Allergic Diseases: pediatric allergy educator text. Practice Part. Tokyo: Shindan To Chiryo Sha Inc; 2013. p. 1-24 (In Japanese).
Armstrong AW, Johnson MA, Lin S, Maverakis E, Fazel N, Liu FT. Patient-centered, direct-access online care for management of atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2015;151:154-60.
Kornmehl H, Singh S, Johnson MA, Armstrong AW. Direct-access online care for the management of atopic dermatitis: A randomized clinical trial examining patient quality of life. Telemed J E Health. 2017;23:726-32.
van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, van der Zalm A, de Bruin-Weller MS, Pasmans SGMA, et al. E-health in caring for patients with atopic dermatitis: a randomized controlled cost-effectiveness study of internet-guided monitoring and online self-management training. Br J Dermatol. 2012;166:1060-8.
Adachi M, Takamasu T, Inuo C. Hyponatremia secondary to severe atopic dermatitis in early infancy. Pediatr Int. 2019;61:544-50.
Fukui T, Yamaguchi N, Morizane T, Yoshida M, Kojimahara N. (eds)Minds handbook for clinical practice guideline development 2014. Igaku-Shoin Ltd: Tokoyo; 2014 (In Japanese).
Japanese Society for Palliative Medicine. Clinical guidelines for infusion therapy in advanced cancer patients 2013. Tokyo: Kanehara & Co., Ltd; 2013 (In Japanese).
Gehring W, Gloor M. Treatment of the atopic dermatitis with a water-in-oil emulsion with or without the addition of hydrocortisone-results of a controlled double-blind randomized study using clinical evaluation and bioengineering methods. Z Hautkr. 1996;71:554-60.
Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997;19:710-9.
Lupton ES, Abbrecht MM, Brandon ML. Short-term topical corticosteroid therapy (halcinonide ointment) in the management of atopic dermatitis. Cutis. 1982;30:671-5.
Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple application of halcinonide cream. Int J Drematol. 1981;20:609-13.
Wahlgren CF, Hägermark O, Bergström R, Hedin B. Evaluation of new method of assessing pruritus and antipruritic drugs. Skin Pharmacol. 1988;1:3-13.
Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis. 1996;57(2 Suppl):62-8.
Breneman D, Fleischer AB Jr, Kaplan D, Lebwohl M, Miller B, Pariser D, et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol. 2005;4:330-6.
Matheson R, Kempers S, Breneman D, Draelos Z, Johnson CE, Loss R, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7:266-71.
Kimball AB, Gold MH, Zib B, Davis MW. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol. 2008;59:448-54.
Nankervis H, Thomas KS, Delamerè FM, Barbarot S, Smith S, Rogers NK, et al. What is the evidence of base for atopic eczema treatment? A summary of published randomized controlled trials. Br J Dermatol. 2017;176:910-27.
Bleehen SS, Chu AC, Hamann I, Holden C, Hunter JA, Marks R. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995;133:592-7.
Koopmans B, Andersen BL, Mørk NJ, Austad J, Suhonen R, Roders GA. Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily. J Dermatol Treat. 1995;6:103-6.
Kerscher MJ, Korting HC, Mehringer L, Matzig R. 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects. Skin Pharmacol. 1996;9:120-3.
Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2002;15:85-91.
Faergemann J, Christensen O, Sjovall P, Johnsson A, Hersle K, Nordin P, et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000;14:393-6.
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338-51.
Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Hooteghem OV, Allegra F, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326:1367.
Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol. 2009;20:59-66.
Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol. 2002;147:528-37.
Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158:801-7.
Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol. 1999;140:1114-21.
Igarashi A, Fujita H, Arima K, Inoue T, Dorey J, Fukushima A, et al. Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis. J Dermatol. 2019;46:652-61.
Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46:290-300.
Wu KK, Borba AJ, Deng PH, Armstrong AW. Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. J Dermatolog Treat. 2021;32:455-9.
Cowan A, Klauder JV. Frequency of occurrence of cataract in atopic dermatitis. Arch Ophthal. 1950;43:759-68.
George SM, Karanovic S, Harrison DA, Rani A, Birnie AJ, Bath-Hextall FJ, et al. Interventions to reduce Staphylococcus aureus in the management of eczema. Cochrane Database Syst Rev. 2019;2019:CD003871.
Schnopp C, Ring J, Mempel M. The role of antibacterial therapy in atopic eczema. Expert Opin Pharmacother. 2010;11:929-36.
Rastogi S, Patel KR, Singam V, Silverberg JI. Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis. J Am Acad Dermatol. 2018;79:1028-1033. e6.
Suzuki K, Matsunaga K, Yagami A, Adachi A, Ikezawa Y, Ito A, et al. Positive rates in 2013 and 2014 of Japanese Standard Allergens 2008. J Environ Dermatol Cutan Allergol. 2017;11:234-47. (In Japanese with English abstract).
Doss N, Kamoun MR, Dubertret L, Cambazard F, Ramitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21:321-9.
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ. 2005;350:516-22.
El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2009;54:76-87.
Svesson A, Chambers C, Gånemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27:1395-406.
Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203-21.
Torii Pharmaceutical Co., Ltd. CORECTIM® Ointment 0.5%, Drug interview form, May 2021 (5th edition). Accessed May 16, 2022. Available from: https://www.info.pmda.go.jp/go/pack/2699714M1029_1_06/?view=frame&style=XML&lang=ja (In Japanese).
Ohtsuki M, Shiragasawa C, So M, Nakagawa H. The long-term safety and effectiveness of 0.03% tacrolimus ointment in the treatment of pediatric patients with atopic dermatitis ‘interim report of long-term special drug use results survey’. J Pediatr Dermatol. 2013;32:127-37.
Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214:289-95.
Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159:942-51.
Arellano FM, Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger R, Corde E, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123:1111-6.
Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrel D, Paul C, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;72:992-1002.
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;2015:CD009864.
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
Castellsague J, Kuiper JG, Pottegård A, Berglind IA, Dedman D, Gutierrez L, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation-JOELLE study). Clin Epidemiol. 2018;10:299-310.
Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacotherapy. 2009;43:1956-63.
Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: Evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163-78.
Study Group of Adult Atopic Dermatitis. Studies on usefulness of antiallergic agent for adult type atopic dermatitis. Comparative studies between single external use of steroid and combined use with oxatomide. Nishinihon J Dermatol. 1989;51:995-1002. (In Japanese).
Hamada T, Ishii M, Nakagawa K, Kobayashi H, Kitajima J, Chaniki M, et al. Evaluation of the clinical effect of terfenadine in patients with atopic dermatitis. A comparison of strong topical corticosteroid therapy to mild topical corticosteroid combined with terfenadine administration therapy. Skin Res. 1996;38:97-103. (In Japanese with English abstract).
Hashizume H, Takigawa M. Clinical efficacy of loratadine for the pruritus associated with atopic dermatitis. Allergy Pract. 2004;24:1105-11. (In Japanese).
Kawashima M, Miyachi Y. Exploratory study on the benefits of an antihistamine (levocetirizine) in maintaining remission in atopic dermatitis (A preliminary randomized comparative study investigating the combined effects of proactive therapy using topical agents). J Clin Therap Med. 2017;33:33-44. (In Japanese with English abstract).
Kawashima M, Sato S, Hide M, Furue M, Miyachi Y. A study on the effect of combined antihistamine and topical proactive treatment on atopic dermatitis. J Clin Therap Med. 2017;33:429-40. (In Japanese with English abstract).
Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multi-centre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol. 2003;148:1212-21.
Hide M, Hirata K, Komorita N, Kubo H, Suzuki T, Tanaka R, et al. Usefulness of Rupatadine for pruritus of patients with atopic dermatitis ‘post hoc analysis of phase III clinical trial for Japanese patients with pruritus associated with skin diseases’. Jpn J Allergol. 2020;69:174-83. (In Japanese).
Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ, The Netherlands Adult Atopic Dermatitis Study Group. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol. 1999;140:1114-21.
Rubio-Gomis E, Martinez-Mir I, Morales-Olivas FJ, Martorell-Aragores A, Palop-Larrea V, Bernalte-Sese A, et al. Fluticasone in mild to moderate atopic dermatitis relapse: a randomized controlled trial. Allergol Immunopathol. 2018;46:378-84.
Liu L, Ong G. A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis. J Dermatolog Treat. 2018;29:501-9.
Fukuie T, Hirakawa S, Narita M, Nomura I, Matsumoto K, Tokura Y, et al. Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study. J Dermatol. 2016;43:1283-92.
Chung BY, Kim HO, Kim JH, Cho SI, Lee CH, Park CW. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. Br J Dermatol. 2013;168:908-10.
Poole CD, Chambers C, Sidhu MK, Currie CJ. Healthrelated utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. Br J Dermatol. 2009;161:1335-40.
Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159:1348-56.
Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63:742-50.
Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58:990-9.
Wilhelm KP, Scholermann A. Efficacy and tolerability of a topical preparation containing 10% urea in patients with atopic dermatitis. Aktuel Dermatol. 1998;24:37-8.
Loden M, Andersson AC, Andersson C, Frodin T, Oman H, Lindberg M. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. Skin Res Technol. 2001;7:209-13.
Boralevi F, Saint Aroman M, Delarue A, Raudsepp H, Kaszuba A, Bylaite M, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28:1456-62.
Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr JW. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21:39-45.
Hamada M, Gyoutoku T, Sato Matsuda T, Matsuda T, Kinukawa N, S, et al. The usefulness of camellia oil spray for treatment of atopic dermatitis. Nishinihon J Dermatol. 2008;70:213-8. (In Japanese).
Matsunaka H, Abe Y, Ooe M, Nishigori C, Miyachi Y. Clinical evaluation of OLIGOMARINE on atopic dry skin. Skin Res. 2004;3:73-83. (In Japanese with English abstract).
Szczepanowska J, Reich A, Szepietowski LC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19:614-8.
Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009;23:1267-72.
Tiplica GS, Boralevi F, Konno P, Malisnanskiene L, Kaszuba A, Laurens C, et al. The regular use of an emollient improves symptoms of atopic dermatitis in children: a randomized controlled study. J Eur Acad Dermatol Venereol. 2018;32:1180-7.
Angelova-Fischer I, Rippke F, Richter D, Filbry A, Arromitz C, Weber T, et al. Standalone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis: A double-blind, randomized, vehicle-controlled, left-right comparison study. Acta Derm Venereol. 2018;98:517-23.
Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62:151-61.
Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4:771-88.
Dissanayake E, Tani Y, Nagai K, Sahara M, Mitsuishi C, Togawa Y, et al. Skin care and synbiotics for prevention of atopic dermatitis and food allergy in newborn infants: A 2 × 2 factorial, randomized, non-treatment controlled trial. Int Arch Allergy Immunol. 2019;180:202-11.
Chalmers JR, Haines RH, Bradshaw LE, Montgomery A, Thomas KS, Brown SJ, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020;395:962-72.
Skjerven HO, Rehbinder EM, Vettukattil R, LeBlanc M, Granum B, Haugen G, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2020;395:951-61.
Hon KL, Leung TF, Wong Y, So HK, Li AM, Fok TF. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005;30:351-4.
Heyer GR, Hornstein OP. Recent studies of cutaneous nociception in atopic and non-atopic subjects. J Dermatol. 1999;26:77-86.
Kameyoshi Y, Tanaka T, Mochizuki M, Koro O, Mihira S, Hiragun T, et al. Taking showers at the school is beneficial for the children with severe atopic dermatitis. Jpn J Allergol. 2008;57:130-7. (In Japanese with English abstract).
Mochizuki H, Muramatsu R, Tadaki H, Mizuno T, Arakawa H, Morikawa A. Effects of skin care with shower therapy on children with atopic dermatitis in elementary schools. Pediatr Dermatol. 2008;26:223-5.
Murota H, Takahashi A, Nishioka M, Matsui S, Terao M, Kitaba S, et al. Showering reduces atopic dermatitis in elementary school students. Eur J Dermatol. 2010;20:410-1.
Maeda N, Yoshida N, Nishino H, Kataoka Y. The clinical significance of serum TARC as a biomarker for severe adult atopic dermatitis. J Environ Dermatol Cutan Allergol. 2011;5:27-35. (In Japanese with English Abstract).
Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107:535-41.
Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, Jong ED, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004;113:334-40.
Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. Biomarkers for atopic dermatitis: a systemic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15:453-60.
Miyamoto K. HISCL® TARC Assay Kit makes it possible to measure serum TARC test rapidly in the hospital laboratory. The Allergy in practice. 2016;36:1155-7. (In Japanese).
Campbell B, De'Ambrosis B. Squamous cell carcinoma antigen in patients with cutaneous disorders. J Am Acad Dermatol. 1990;22:639-42.
Horiuchi Y, Tsukahara T, Otoyama K. Immunohistochemical study of elevated expression of squamous cell carcinoma (SCC)-related antigens in erythrodermic epidermis. J Dermatol. 1994;21:67-72.
Kawashima H, Nishimata S, Kashiwagi Y, Numabe H, Sasamoto M, Iwatsubo H, et al. Squamous cell carcinoma-related antigen in children with atopic dermatitis. Pediatr Int. 2000;42:448-50.
Mitsuishi K, Nakamura T, Sakata Y, Yuyama N, Arima K, Sugita Y, et al. The squamous cell carcinoma antigens as relevant biomarkers of atopic dermatitis. Clin Exp Allergy. 2005;35:1327-33.
Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137-40.
Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52-8.
Czech W, Bräutigam M, Weidinger G, Schopf E. A bodyweight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol. 2000;42:653-9.
Study Group of Neoral®. Treatment for Atopic Dermatitis: cyclosporine MEPC versus placebo for treating patients with severe adult atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled study. Jpn J Clin Dermatol. 2009;63:73-82. (In Japanese).
Moriwaki S. Point of daily life guidance about ultraviolet light exposure for patients with atopic dermatitis. In: Katoh N, editor. Q&A55 Atopic Dermatitis answered by experts. Tokyo: Sindan To Chiryo Sha; 2014. p. 121-3 (In Japanese).
Juzeniene A, Moan J. Beneficial effects of UV radiation other than via vitamin D production. Dermatoendocrinol. 2012;4:109-17.
Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015;8:511-20.
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:22-31.
Man I, Crombie IK, Dawe RS, Ibbotson SH, Ferguson J. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol. 2005;152:755-7.
Osmancevic A, Gillstedt M, Wennberg AM, Larko O. The risk of skin cancer in psoriasis patients treated with UVB therapy. Acta Derm Venereol. 2014;94:425-30.
Hearn RM, Kerr AC, Rahlm KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008;159:931-5.
Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, et al. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a sub analysis of three clinical trials. Br J Dermatol. 2020;183:39-51.
Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78:62-9.
Eichenfield LF, Bieber T, Beck LA, Simpson EL, ThaçI D, de Bruin-Weller M, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20:443-56.
Tan HY, Zhang AL, Chen D, Xue CC, Lenon GB. Chinese herbal medicine for atopic dermatitis: a systematic review. J Am Acad Dermatol. 2013;69:295-304.
Hon KL, Leung TF, Ng PC, Lam MCA, Kam WYC, Wong KY, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2007;157:357-63.
Gu SX, Mo X, Zhang AL, Liu J, Coyle ME, Ye S, et al. A Chinese herbal medicine preparation (Pei Tu Qing Xin) for children with moderate-to-severe atopic eczema: a pilot randomized controlled trial. Br J Dermatol. 2018;179:1404-5.
Liu J, Mo X, Wu D, Ou A, Xue S, Liu C, et al. Efficacy of a Chinese herbal medicine for the treatment of atopic dermatitis: a randomised controlled study. Complement Ther Med. 2015;23:644-51.
Yanagihara S. EBM with traditional Chinese herbal medicines for atopic dermatitis. J Jpn Assoc Orient Psychosom Med. 2019;34:68-72. (In Japanese).
Holm L, Bengtsson A, van Hage-Hamsten M, Ohman S, Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis - a placebo-controlled trial of 12 months' duration. Allergy. 2001;56:152-8.
Ricci G, Patrizi A, Specchia F, Menna L, Bottau P, D'Angelo V, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol. 2000;143:379-84.
Friedmann PS, Tan BB. Mite elimination - clinical effect on eczema. Allergy. 1998;53(48 Suppl):97-100.
Tan BB, Weald D, Strickland I, Friedmann PS. Doubleblind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347:15-8.
Sanda T, Yasue T, Oohashi M, Yasue A. Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol. 1992;89:653-7.
Oosting AJ, de Bruin-Weller MS, Terreehorst I, Tempels-Pavlica Z, Abalberse R, de Monchy JGR, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol. 2002;110:500-6.
Gutgesell C, Heise S, Seubert S, Seubert A, Domhof S, Brunnor E, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol. 2001;145:70-4.
Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev. 2015;2015:CD008426.
Nanbu M. Indoor allergen avoidance for allergic children. Jpn J Pediatr Allergy Clin Immunol. 2010;24:203-16. (In Japanese with English abstract).
Atherton DJ, Sewell M, Soothill JF, Wells RS, Chilvers CE. A double-blind controlled crossover trial of an antigen-avoidance diet in atopic eczema. Lancet. 1978;1:401-3.
Neild VS, Marsden RA, Bailes JA, Bland JM. Egg and milk exclusion diets in atopic eczema. Br J Dermatol. 1986;114:117-23.
Cant AJ, Bailes JA, Marsden RA, Hewitt D. Effect of maternal dietary exclusion on breast fed infants with eczema: two controlled studies. Br Med J. 1986;293:231-3.
Lever R, MacDonald C, Waugh P, Aitchison T. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol. 1998;9:13-9.
Niggemann B, Binder C, Dupont C, Hadji S, Arvola T, Isolauri E. Prospective, controlled, multi-center study on the effect of an amino-acid-based formula in infants with cow's milk allergy/intolerance and atopic dermatitis. Pediatr Allergy Immunol. 2001;12:78-82.
Isolauri E, Sutas Y, Makinen-Kiljunen S, Oja SS, Isosomppi R, Turjanmaa K. Efficacy and safety of hydrolyzed cow milk and amino acid-derived formulas in infants with cow milk allergy. J Pediatr. 1995;127:550-7.
Mabin DC, Sykes AE, David TJ. Controlled trial of a few foods diet in severe atopic dermatitis. Arch Dis Child. 1995;73:202-7.
Munkvad M, Danielsen L, Hoj L, Povlsen CO, Secher L, Svejgaard E, et al. Antigen-free diet in adult patients with atopic dermatitis. A double-blind controlled study. Acta Derm-Venereol. 1984;64:524-8.
Leung TF, Ma KC, Cheung LT, Lam CWK, Wong E, Wan H, et al. A randomized, single-blind and crossover study of an amino acid-based milk formula in treating young children with atopic dermatitis. Pediatr Allergy Immunol. 2004;15:558-61.
Hourihane JO, Aiken R, Briggs R, Gudgeon LA, Grimshaw KEC, DunnGalvin A, et al. The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol. 2007;119:1197-202.
Dean T, Venter C, Pereira B, Grundy J, Clayton CB, Higgins B. Government advice on peanut avoidance during pregnancy - is it followed correctly and what is the impact on sensitization? J Hum Nutr Diet. 2007;20:95-9.
Herrmann ME, Dannemann A, Gruters A, Radisch B, Dudenhausen JN, Bergmann R, et al. Prospective study on the atopy preventive effect of maternal avoidance of milk and eggs during pregnancy and lactation. Eur J Pediatr. 1996;155:770-4.
Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: Follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol. 1995;95:1179-90.
Arshad SH, Bateman B, Sadeghnejad A, Gant C, Matthews SM. Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. J Allergy Clin Immunol. 2007;119:307-13.
Hattevig G, Sigurs N, Kjellman B. Effects of maternal dietary avoidance during lactation on allergy in children at 10 years of age. Acta Paediatr. 1999;88:7-12.
Frank L, Marian A, Visser M, Weinberg E, Potter PC. Exposure to peanuts in utero and in infancy and the development of sensitization to peanut allergens in young children. Pediatr Allergy Immunol. 1999;10:27-32.
Sicherer SH, Wood RA, Stablein D, Lindblad R, Burks AW, Liu AH, et al. Maternal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants. J Allergy Clin Immunol. 2010;126:1191-7.
Greer FR, Sicherer SH, Burks AW. The effects of early nutritional interventions on the development of atopic disease in infants and children: The role of maternal dietary restriction, breastfeeding, hydrolyzed formulas, and timing of introduction of allergenic complementary foods. Pediatrics. 2019;143:e20190281.
Bédard A, Northstone K, Henderson AJ, Shaheen SO. Maternal intake of sugar during pregnancy and childhood respiratory and atopic outcomes. Eur Respir J. 2017;50:1700073.
Pretorius RA, Bodinier M, Prescott SL, Palmer DJ. Maternal fiber dietary intakes during pregnancy and infant allergic disease. Nutrients. 2019;11:1767.
Cuello-Garcia CA, Brożek JL, Fiocchi A, Pawankar R, Yepes-Nunez JJ, Terracciano L, et al. Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2015;136:952-61.
Li L, Han Z, Niu X, Zhang G, Jia Y, Zhang S, et al. Probiotic supplementation for prevention of atopic dermatitis in infants and children: A systematic review and meta-analysis. Am J Clin Dermatol. 2019;20:367-77.
Mansfield JA, Bergin SW, Cooper JR, Olsen CH. Comparative probiotic strain efficacy in the prevention of eczema in infants and children: a systematic review and meta-analysis. Mil Med. 2014;179:580-92.
Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;2007:CD006475.
Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev. 2013;2003:CD006474.
Sánchez J, Sánchez MR, Macías-Weinmann A, Barreto B, Ensina LF, Uriarte-Obando SA, et al. Systematic review about 10 interventions in dermatitis. A document from the Latin American Society of Allergy, Asthma, and Immunology. Rev Alerg Mex. 2019;66:426-55.
Szajewska H, Horvath A. Lactobacillus rhamnosus GG in the primary prevention of eczema in children: a systematic review and meta-analysis. Nutrients. 2018;10:1319.
Zuccotti G, Meneghin F, Aceti A, Barone G, Callegri ML, Di Mauro A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy. 2015;70:1356-71.
Kuitunen M, Kukkonen K, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, et al. Probiotics prevent IgE-associated allergy until age 5 years in Cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol. 2009;123:335-41.
Simpson MR, Dotterud CK, Storrø O, Johnsen R, Øien T. Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial. BMC Dermatol. 2015;15:13.
West CE, Hammarström ML, Hernell O. Probiotics in primary prevention of allergic disease - follow-up at 8-9 years of age. Allergy. 2013;68:1015-20.
Okano S, Takahasi H, Yano T, Yamura M, Niimi N, Tanaka K, et al. Member posted first grade school children after five years of skin lesions, including atopic dermatitis with prognosis Survey: Study in Hiroshima Prefecture Asa district. J Jpn Med Assoc. 2006;135:97-103. (In Japanese).
Arima T, Kohno Y. The present study about the prevalence of atopic dermatitis in Japan. Allergy Pract. 2009;29:581-7. (In Japanese).
Hua TC, Hwang CY, Chen YJ, Chu S-Y, Chen C-C, Lee D-D, et al. The natural course of early-onset atopic dermatitis in Taiwan: a population-based cohort study. Br J Dermatol. 2014;170:130-5.
von Kobyletzki LB, Bomehag CG, Breeze E, Larsson M, Lindstrom CB, Svensson A. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol. 2014;94:179-84.
Wan J, Mitra N, Hoffstad OJ, Yan AC, Margolis DJ. Longitudinal atopic dermatitis control and persistent vary with timing of disease onset in children: a cohort study. J Am Acad Dermatol. 2019;81:1292-9.
Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol. 1997;14:119-24.
Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf. 2017;40:121-32.
Schwarz EB, Moretti ME, Nayak S, Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf. 2008;31:775-88.
Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Barker D, Ballmer-Weber B, et al. The EAACI/GA (2) LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy. 2018;73:1393-414.
Andersson NW, Poulsen HE, Andersen JT. Desloratadine use during pregnancy and risk of adverse fetal outcomes: A nationwide cohort study. J Allergy Clin Immunol Pract. 2020;8:1598-605.
Golembesky A, Cooney M, Boev R, Schlit AF, Bentz JWG. Safety of cetirizine in pregnancy. J Obstet Gynaecol. 2018;38:940-5.
Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol. 2008;26:19-23.
Andersson NW, Torp-Pedersen C, Andersen JT. Association between fexofenadine use during pregnancy and fetal outcomes. JAMA Pediatr. 2020;174:e201316.
Hansen C, Desrosiers TA, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: the National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 2020;112:1234-52.
Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breastfed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168:1393-9.
Hilbert J, Radwanski E, Affrime MB, Perentesis G, Symchowicz S, Zampaglione N. Excretion of loratadine in human breast milk. J Clin Pharmacol. 1988;28:234-9.
Lucas BD Jr, Purdy CY, Scarim SK, Benjamin S, Abel SR, Hilleman DE. Terfenadine pharmacokinetics in breast milk in lactating women. Clin Pharmacol Ther. 1995;57:398-402.
Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol. 2019;33:577-87.
Inuzuka Y, Natsume O, Matsunaga M, Monna Y, Okua E, Kato Y, et al. Washing with water alone versus soap in maintaining remission of eczema. Pediatr Int. 2020;62:663-8.
White MI, Jenkinson DM, Lloyd DH. The effect of washing on the thickness of the stratum corneum in normal and atopic individuals. Br J Dermatol. 1987;116:525-30.
Ananthapadmanabhan KP, Moore DJ, Subramanyan K, Misra M, Meyer F. Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther. 2004;17(Suppl 1):16-25.
Joichi M, Nishida F, Ohata N. Efficacy of genital wash with baby bathing agents/body soap/foamy body soap. Collected papers by the Japanese Nursing Association: Comprehensive Nursing. 2014;44:52-5. (In Japanese).
Yamaguchi K. Drug therapy in perinatal period. Perinat Med. 1995;25:405-7. (In Japanese).
Takahashi E, Suzuki H, Yamamoto K. Skin caring in children. Comparative study of newborn bathing by baby bath oil and soaps. J Pediatr Dermatol. 1990;9:204-12. (In Japanese).
Nashiro M, Chiba M, Nakata T, Ishibashi H, Masuda S, Zenke T. Evaluation of the preventive effects of baby bathing agents on dry skin based on measurement of the stratum corneum water content after whole body bed-bath/foot bath with baby bathing agents and hot water. Ashi. 2007;38:149-51. (In Japanese).
Lavender T, Bedwell C, Roberts SA, Hart A, Turner MA, Carter L-A, et al. Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates. J Obstet Gynecol Neonatal Nurs. 2013;42:203-14.
Izumisawa S, Takei Y, Tanabe M, Miyashita S, Fukuyama K, Okawa T, et al. Comparison of several bath additives. Jap J Midwives. 1976;30:357-61. (In Japanese).
Kawaida N, Uemura M, Kida S, Nishiura J, Isaji M, Nii R, et al. Skin care from the neonatal period. Child health. 2016;19:935-8. (In Japanese).
Maarouf M, Hendricks AJ, Shi VY. Bathing additives for atopic dermatitis - A systematic review. Dermatitis. 2019;30:191-7.
Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-21.
Sugimoto K, Kuroki H, Kanazawa M, Kurosaki T, Abe H, Takahashi Y, et al. New successful treatment with disinfectant for atopic dermatitis. Dermatology. 1997;195(Suppl 2):62-8.
Uenishi T, Uehara M. Evaluation of popidone-iodine antiseptic solution. Rinsho Derma (Tokyo). 1998;40(Suppl 38):984-7. (In Japanese).
Iijima S, Kuramochi M. Irritant contact dermatitis caused by 10% povidone-iodine solution after an operation. Jpn J Dermatol. 1999;109:1029-41. (In Japanese with English Abstract).
Pedrosa C, Costa H, Oliveira G, Romariz J, Praca F. Anaphylaxis to povidone in a child. Pediatr Allergy Immunol. 2005;16:361-2.
Myles IA, Earland NJ, Anderson ED, Moore IN, Kieh MD, Williams KW, et al. First-inhuman topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3:e120608.
Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol. 2013;40:874-80.
Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123:e808-14.
Hon KL, Tsang YCK, Lee VWY, Pong NH, Ha G, Lee ST, et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema: a randomized, placebo-controlled cross-over trial. J Dermatolog Treat. 2016;27:156-62.
Shi VY, Foolad N, Ornelas JN, Hassoun LA, Monico G, Takeda N, et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split-body randomized controlled trial. Br J Dermatol. 2016;175:212-4.
Sasaki R. Skin care for atopic dermatitis children in group life. Jpn J Allergol. 2016;65:974-80. (In Japanese).
Biniek K, Levi K, Dauskardt RH. Solar UV radiation reduces the barrier function of human skin. Proc Natl Acad Sci USA. 2012;109:17111-6.
Nin M, Katoh N, Kokura S, Handa O, Yoshikawa T, Kishimoto S. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes. J Dermatol Sci. 2009;54:17-24.
Deguchi H, Danno K, Sugiura H, Uehara M. Sun exposure is an aggravating factor responsible for the recalcitrant facial erythema in adult patients with atopic dermatitis. Dermatology. 2002;204:23-8.
Uchida M, Miki K, Mitsui T, Futaishi Y, Matsumoto M, Yamamoto K. In vitro and clinical evaluation of SSP UV-care cream for children with atopic dermatitis. J Pediatr Dermtol. 2003;22:179-85.
Ueno M, Takayama K, Yasuhara M, Yokozeki H. Clinical experience of hypoallergenic sunscreen use in patients with sensitive skin due to atopic dermatitis or contact dermatitis. Allergol Immunol. 2016;23:1129-36. (In Japanese).
Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L. Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. J Allergy Clin Immunol. 2013;132:616-22.
Stelmach I, Bobrowska-Korzeniowska M, Smejda K, Majek P, Jerzynska J, Stelmach W, et al. Risk factors for the development of atopic dermatitis and early wheeze. Allergy Asthma Proc. 2014;35:382-9.
Zirngibl A, Franke K, Gehring U, von Berg A, Berdel D, Bauer CP, et al. Exposure to pets and atopic dermatitis during the first two years of life. A cohort study. Pediatr Allergy Immunol. 2002;13:394-401.
Yonekura Y, Katayama I, Murota H. Seroprevalence of cat- and dog-specific IgEs in atopic dermatitis without history of pet parenting. J Cutan Immunol Allergy. 2018;1:149-51.

Auteurs

Hidehisa Saeki (H)

Department of Dermatology, Nippon Medical School, Tokyo, Japan.
ORCID: 0000-0002-1095-0355

Yukihiro Ohya (Y)

Allergy Center, National Center for Child Health and Development, Tokyo, Japan.

Junichi Furuta (J)

Medical Informatics and Management, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
ORCID: 0000-0002-3502-5780

Hirokazu Arakawa (H)

Kitakanto Allergy Research Institute, Kibounoie Hospital, Midori, Japan.

Susumu Ichiyama (S)

Department of Dermatology, Nippon Medical School, Tokyo, Japan.
ORCID: 0000-0003-1508-9514

Toshio Katsunuma (T)

Department of Pediatrics, The Jikei University Daisan Hospital, Tokyo, Japan.

Norito Katoh (N)

Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
ORCID: 0000-0002-3498-2482

Akio Tanaka (A)

Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
ORCID: 0000-0002-5354-7064

Yuichiro Tsunemi (Y)

Department of Dermatology, Saitama Medical University, Saitama, Japan.
ORCID: 0000-0003-3590-6489

Takeshi Nakahara (T)

Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID: 0000-0003-2811-8273

Mizuho Nagao (M)

Allergy Center, National Hospital Organization Mie National Hospital, Tsu, Japan.

Masami Narita (M)

Department of Pediatrics, Faculty of Medicine, Kyorin University, Tokyo, Japan.

Michihiro Hide (M)

Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.
ORCID: 0000-0002-1569-6034

Takao Fujisawa (T)

Allergy Center, National Hospital Organization Mie National Hospital, Tsu, Japan.

Masaki Futamura (M)

Division of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Koji Masuda (K)

Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.

Tomoyo Matsubara (T)

Department of Pediatrics, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.

Hiroyuki Murota (H)

Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
ORCID: 0000-0002-0450-1377

Kiwako Yamamoto-Hanada (K)

Allergy Center, National Center for Child Health and Development, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Eczéma atopique › English Version of Clinical Practice...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Produits dermatologiques › Émollient › English Version of Clinical Practice...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Glucocorticoïdes › English Version of Clinical Practice...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › English Version of Clinical Practice...
Recherchemedicale.com › Préparations pharmaceutiques › Onguents › English Version of Clinical Practice...
Recherchemedicale.com › Composés chimiques organiques › Lactones › Tacrolimus › English Version of Clinical Practice...